Cargando…
Multiple sclerosis
Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of mult...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
College of Psychiatric & Neurologic Pharmacists
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881109/ https://www.ncbi.nlm.nih.gov/pubmed/31857931 http://dx.doi.org/10.9740/mhc.2019.11.349 |
_version_ | 1783473884027158528 |
---|---|
author | Klocke, Shilpa Hahn, Nicole |
author_facet | Klocke, Shilpa Hahn, Nicole |
author_sort | Klocke, Shilpa |
collection | PubMed |
description | Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis. Disease-modifying therapies are now being classified into categories based on level of efficacy. Strategies to use disease-modifying therapies earlier and in a more customizable manner are also emerging. A clinical case study will be used throughout this pearl to review the disease-modifying therapies and use patient-specific factors to develop and provide recommendations on therapeutic strategies for individuals with relapsing forms of multiple sclerosis. |
format | Online Article Text |
id | pubmed-6881109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | College of Psychiatric & Neurologic Pharmacists |
record_format | MEDLINE/PubMed |
spelling | pubmed-68811092019-12-19 Multiple sclerosis Klocke, Shilpa Hahn, Nicole Ment Health Clin Psychopharmacology Pearls Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis. Disease-modifying therapies are now being classified into categories based on level of efficacy. Strategies to use disease-modifying therapies earlier and in a more customizable manner are also emerging. A clinical case study will be used throughout this pearl to review the disease-modifying therapies and use patient-specific factors to develop and provide recommendations on therapeutic strategies for individuals with relapsing forms of multiple sclerosis. College of Psychiatric & Neurologic Pharmacists 2019-11-27 /pmc/articles/PMC6881109/ /pubmed/31857931 http://dx.doi.org/10.9740/mhc.2019.11.349 Text en © 2019 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Psychopharmacology Pearls Klocke, Shilpa Hahn, Nicole Multiple sclerosis |
title | Multiple sclerosis |
title_full | Multiple sclerosis |
title_fullStr | Multiple sclerosis |
title_full_unstemmed | Multiple sclerosis |
title_short | Multiple sclerosis |
title_sort | multiple sclerosis |
topic | Psychopharmacology Pearls |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881109/ https://www.ncbi.nlm.nih.gov/pubmed/31857931 http://dx.doi.org/10.9740/mhc.2019.11.349 |
work_keys_str_mv | AT klockeshilpa multiplesclerosis AT hahnnicole multiplesclerosis |